Update on Growth Disorders

Speciality: Pediatrics


Speaker:

Dr. Leena Priyambada - Moderator | MD-Pediatrics (PGIMER), Pediatric Endocrinology (SGPGI), Consultant Pediatric Endocrinologist

Dr. Vaishakhi Rustagi - Speaker | MBBS, MD Pediatrics (Gold Medalist), Post Doctoral Clinical Fellowship in Pediatric Endocrinology, Consultant Pediatric & Adolescents Endocrinologist

Dr. Hemchand K Prasad - Speaker | Consultant Department of Pediatric & Endocrinology & Diabetes

Description:

A warm welcome to all the medical professionals in this interesting session on Update on Growth Disorders
Recent advancements in the understanding and management of growth disorders have significantly improved outcomes for affected children. Growth disorders, such as growth hormone deficiency (GHD), Turner syndrome, and idiopathic short stature (ISS), often require early diagnosis and intervention for optimal growth and development. The use of recombinant human growth hormone (rhGH) therapy has been a cornerstone in treating many of these conditions, demonstrating substantial benefits in promoting height gain and improving overall health.
Genetic and molecular research has expanded knowledge of the underlying causes of various growth disorders, leading to more precise diagnostic tools and personalized treatment approaches. Innovations in genetic testing can now identify specific mutations responsible for growth impairments, allowing for targeted therapies that address the root causes. Additionally, emerging treatments, such as growth hormone secretagogues and insulin-like growth factor-1 (IGF-1) therapy, offer new avenues for managing growth disorders. Ongoing clinical trials and research continue to refine these therapies, aiming to enhance efficacy and minimize side effects, ultimately improving the quality of life for children with growth disorders.
Therefore, get an overall knowledge of update on growth disorders
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

2.

Team finds broken 'brake' on cancer mutation machine.

3.

Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot